CorMedix CEO Joseph Todisco Extends Contract, Becomes Chairman Of The Board As Myron Kaplan Transitions to Lead Independent Director; Mike Seckler Joins As EVP & Chief Commercial Officer

CorMedix Therapeutics, a biopharmaceutical company focused on developing and commercializing treatments for life-threatening diseases and conditions, announced important updates to its executive leadership team and Board of Directors. The company shared that CEO Joseph Todisco has signed an extended employment agreement, reaffirming his long-term commitment to CorMedix. Along with continuing his role as Chief Executive Officer, Mr. Todisco will also take on the additional responsibility of Chairman of the Board, succeeding Myron Kaplan. Mr. Kaplan will move into a new role as Lead Independent Director, a position created to further support the Board’s governance structure.

Reflecting on the transition, Myron Kaplan noted that under Mr. Todisco’s leadership, CorMedix has grown from a single-product, development-stage company into a diversified commercial organization with multiple products, positive cash flow, and a promising pipeline. He added that Mr. Todisco’s appointment as Chairman strengthens CorMedix and positions the company well for continued growth.

CorMedix also announced the appointment of Mike Seckler as Executive Vice President and Chief Commercial Officer. Mr. Seckler brings extensive experience across therapeutic areas such as hematology and oncology. Most recently, he served as CEO of Evome Medical Technologies Inc. His earlier leadership roles include serving as Chief Operating Officer at FerGene Inc., a gene therapy company backed by Blackstone Life Sciences and Ferring Pharmaceuticals, and leading global marketing and corporate communications at Ferring International.

Commenting on the organizational updates, Joseph Todisco said he is pleased to welcome Mr. Seckler to the leadership team, noting that his commercial expertise will be especially valuable as CorMedix advances both its base business and preparations for future product launches. He also expressed his appreciation for Myron Kaplan’s guidance and support during their years working together. With a solid leadership team now in place, Mr. Todisco shared his optimism about the company’s future direction.